Announcement PDF ASX RELEASE 14 April 2025 Emyria Opens Second Empax Clinic to Meet Growing Demand and Payer Requirements Key Highlights: • • • • • • • New Empax Centre now open within Perth Clinic, licensed day hospital, expanding capacity by 50% First two patients to commence treatment on April 14 Embedded within licensed facility to meet requirements of payers set to fund Empax treatment Emyria now delivering programs for both PTSD and treatment-resistant depression Longer-term follow-up data indicates durable, clinically meaningful outcomes Further Empax Centres planned for the East Coast Expansion aligns with rising national demand and growing payer interest in next-generation mental health care Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), specialising in the development and delivery of innovative treatments for mental health and select neurological conditions, is pleased to announce the official opening of its second Empax Centre, located within Perth Clinic, one of Western Australia’s leading licensed private mental health hospitals. This expansion, which will increase treatment capacity by 50%, is designed to comply with the requirements of major healthcare funders seeking to cover evidence-based mental health therapies within licensed healthcare environments. The first two fully funded patients will commence treatment on April 14, marking the activation of the site and the start of a broader rollout strategy that reflects both rising clinical demand and structural changes in mental health care funding. “We are responding to growing patient demand and the expectations of major health funders,” said Greg Hutchinson, Executive Chair. “Our expansion into licensed hospital settings demonstrates Emyria’s capacity to deliver scalable, evidence-based mental health care treatments.” Strategic Growth & Durability of Outcomes The new site comes as Emyria formally launches its second advanced care program— this time for treatment-resistant depression—in addition to its established PTSD offering. Clinical demand continues to accelerate, and early long-term follow-up suggests that treatment benefits are durable 1 , reinforcing the potential for lasting patient impact and broader system adoption. 1 See ASX release 04 February 2025 Emyria ASX Announcement | 14 April 2025 Executive Director and Chief Scientific Officer, Dr. Winlo, commented: “We are particularly encouraged by the sustained outcomes we’re seeing in patients at our primary Empax Centre. As we continue to follow patients longer term, we’re building valuable real-world data assets in this emerging field — helping us improve our treatments, inform national care models, and support broader system adoption.” Positioned for Payer-Backed Growth The decision to embed Empax Centres within licensed hospital environments reflects a broader strategy to position Emyria to meet the funding criteria of private insurers and major payers now preparing to support innovative care models for conditions like PTSD and treatment-resistant depression. National Expansion Discussions Underway Emyria is currently in active discussions with multiple East Coast hospital partners and clinicians, and is aiming to announce further site openings in 2025. 2 This expansion reflects Emyria’s broader goal: to build a national network of Empax Centres capable of delivering novel mental health care at scale—supported by payers, guided by evidence, and focused on lasting impact. This release has been approved by the Board of Emyria. For further information, investment opportunities, or more about our approach to mental health treatment, please contact: Greg Hutchinson Executive Chair +61 (0) 8 6559 2800 ghutchinson@emyria.com About Perth Clinic: Perth Clinic is a private psychiatric hospital renowned for providing quality in-patient and day-patient psychiatric care. As a nationally recognised centre of excellence, the 100-bed hospital provides specialist clinical services within a heritage setting. Perth Clinic believes that by creating an atmosphere of care, trust, and respect for its patients, and by offering innovative, effective, and outcome-driven programs, it can better meet the individual needs of patients. This patient-centred approach ensures that patients receive relevant, timely, and high-quality services during their treatment and throughout their stay. The staff at Perth Clinic comprise a specialised team of health professionals dedicated to providing high-quality, evidence-based care for all patients. By maintaining services of excellence, Perth Clinic continues to lead in the fields of assessment, treatment, evaluation, and research for a wide range of mental health issues. Perth Clinic recognises the importance of each patient's journey to recovery, and its staff are committed to providing the support and care needed to help patients achieve their health goals. At present, no definitive agreements are in place and there are no guarantees that Emyria will be able to secure further sites. 2 Emyria ASX Announcement | 14 April 2025 2 Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: generates Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. informs Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Emyria ASX Announcement | 14 April 2025 3